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Studies of primary ciliary dyskinesia (PCD) have been hampered by
the lack of a suitable animal model because disruption of essential
ciliary genes in mice results in a high incidence of lethal hydroceph-
alus. To develop a viable mouse model for long-term studies of PCD,
we have generated a transgenic mouse line in which two conserved
exons of the mouse intermediate dynein chain gene, Dnaic1, are
flanked by loxP sites (Dnaic1flox/flox). Dnaic1 is the murinehomolog of
human DNAI1, which is mutated in approximately 10% of human
PCD cases. These mice have been crossed with mice expressing
a tamoxifen-inducible Cre recombinase (CreER). Treatment of adult
Dnaic1flox/flox/CreER1/2 mice with tamoxifen results in an almost
complete deletion of Dnaic1 with no evidence of hydrocephalus.
Treated animals have reduced levels of full-length Dnaic1 mRNA,
and electron micrographs of cilia demonstrate a loss of outer dynein
arm structures. In treated Dnaic1flox/flox/CreER1/2 animals, mucocili-
ary clearance (MCC) was reduced over time. After approximately
3 months, no MCC was observed in the nasopharynx, whereas in the
trachea, MCC was observed for up to 6 months, likely reflecting
a difference in the turnover of ciliated cells in these tissues. All
treated animals developed severe rhinosinusitis, demonstrating the
importance of MCC to the health of the upper airways. However, no
evidence of lung disease was observed up to 11 months after Dnaic1
deletion, suggesting that other mechanisms are able to compensate
for the lack of MCC in the lower airways of mice. This model will be
useful for the study of the pathogenesis and treatment of PCD.
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Mucociliary clearance (MCC) is an important innate defense
mechanism of the mammalian lung (1, 2). The cilia, which
provide the force for MCC, and the overlying mucous layer,
which traps inhaled material, are essential for effective MCC.
Impaired MCC is a common feature of many airway diseases
and can be the result of environmental exposure to toxins (e.g.,
cigarette smoke, ozone), pathogens (e.g., bacteria, viruses), or
genetic mechanisms. Patients with genetic defects in MCC
suffer from repeated episodes of airway infection and eventu-
ally develop bronchiectasis. Individuals afflicted with primary
ciliary dyskinesia (PCD), an inherited disease caused by muta-
tions that result in defective cilial function, exhibit chronic
rhinosinusitis, otitis media, and bronchitis, frequently leading to
bronchiectasis (3–6). In cystic fibrosis (CF), mutations in the CF
transmembrane conductance regulator (CFTR) protein result in
a thick mucus layer that prevents effective MCC and results in
the chronic lung disease that causes the majority of mortality
associated with this disease (7, 8). The difference in severity of
the two genetic diseases has been attributed to the fact that
patients with PCD are capable of using cough as an alternative
mechanism of clearance, whereas in CF, the thickened mucus is
not easily removed even by vigorous coughing. Although MCC
and cough are clearly effective in the larger airways, the
mechanisms responsible for the clearance of inhaled particles
from the respiratory bronchioles and alveoli, which lack ciliated
cells, are not well understood.
To investigate the role of MCC and other clearance mecha-
nisms in lung defense, it would be useful to have an animal model
in which MCC has been eliminated by inactivation of the cilia.
However, the inactivation of MCC by targeted deletion of essential
ciliary genes using standard knock-out procedures (9–11), or the
random inactivation of ciliary genes by other techniques (12–16),
usually results in mice with severe developmental defects, including
hydrocephalus and situs ambiguities (15, 17). Thus, although these
animals lack MCC, they typically die from other causes before
reaching adulthood and are largely unsuitable for studying the role
of MCC in the prevention of airway disease.
To develop a model of PCD that replicates features of the
human disease without the high incidence of hydrocephalus and
other developmental abnormalities, we have generated a mouse
model carrying an inducible deletion in a gene coding for an
intermediate dynein chain, Dnaic1. Dnaic1 is the murine homo-
log of the human gene DNAI1 that is mutated in approximately
10% of patients with PCD (18–21). The DNAI1 protein is
a component of the outer dynein arm (ODA), and mutations in
this protein frequently result in the absence of the ODA, as
visible by electron microscopy. By allowing animals homozy-
gous for the conditional deletion to survive the neonatal period
before inducing the deletion in Dnaic1, we hypothesized that
animals with impaired MCC suitable for long-term studies could
be obtained in the absence of hydrocephalus or other develop-
mental abnormalities.
Our data demonstrate that the Cre-mediated deletion of the
Dnaic1 gene occurs with high efficiency and results in the loss of
ODA structures in respiratory cilia. The absence of the ODA
results in ciliary immotility in vitro and in the absence of MCC
in vivo. Animals treated to induce the deletion of Dnaic1 have
survived for up to 11 months with no evidence of hydrocephalus.
CLINICAL RELEVANCE
This report describes the development of a viable mouse
model for the human disease primary ciliary dyskinesia.
The model will be useful for studies of the pathogenesis
and treatment of this and other airway diseases and for
basic studies of ciliary biology and airway clearance.
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These animals develop severe rhinosinusitis, consistent with a
PCD phenotype. This model should be useful for studies of the
pathogenesis and treatment of PCD and other airway diseases.
MATERIALS AND METHODS
General
RNA and DNA were isolated using RNeasy and DNeasy kits (Qiagen
Inc., Valencia, CA) according to the manufacturer’s protocols. Routine
genotyping and analysis were performed using AmpliTaq Gold (Ap-
plied Biosystems, Foster City, CA) or REDExtract-N-Amp kit (Sigma-
Aldrich, St. Louis, MO) and an Applied Biosystems thermocycler with
primers that span the targeted region (primers are listed in Table E1 in
the online supplement). Quantitative PCR to determine the amount of
intact Dnaic1 remaining after tamoxifen treatment was performed
using LightCycler SYBR Green reagents (Roche Applied Science,
Mannheim, Germany) and a Roche LightCycler using primers that
were internal to the deleted region.
Generation of Dnaic1flox/flox Transgenic Animals
Briefly, high-fidelity, long-distance PCR (Takara Bio, Madison, WI)
was used to amplify fragments of mouse genomic DNA surrounding
exons 17 and 18 of Dnaic1. The fragments were cloned into a plasmid
containing the flanking loxP sites and selectable markers. The plasmid
construct was electroporated into ES cells, and neomycin-resistant
clones were screened by Southern analysis. The neomycin cassette was
flanked by FRT sites and was removed using FLP recombinase. The
selected ES cells were injected into mouse blastocysts and transferred
to pseudo-pregnant female mice to allow for development of transgenic
mice carrying the targeted Dnaic1 gene. Mice were genotyped by PCR
of genomic DNA using primers that flank the targeted region. All
animal procedures were approved by the UNC IACUC committee.
Breeding and Tamoxifen Treatment
Dnaic1flox/flox animals were maintained on a mixed background
(C57Bl6/129) and were mated to mice expressing a tamoxifen-inducible
Cre recombinase under control of the Rosa promoter (R26CreER;
Jackson Laboratory, Bar Harbor, ME [22]). Typically, we mated
Dnaic1flox/flox/CreER2/2 mice with Dnaic1wt/flox/CreER1/1 to generate
experimental animals. Tamoxifen (Sigma-Aldrich) was dissolved in
pure corn oil at 10 mg/ml (23). For all studies, Dnaic1flox/flox/CreER1/2
were treated with tamoxifen (five intraperitoneal injections of 75 mg/g
body weight) to generate PCD animals. In most experiments, PCD
animals were compared with Dnaic1wt/flox or Dnaic1wt/wt that were also
treated with tamoxifen. In early studies, we found that treating younger
animals (3–4 wk of age) or administering the tamoxifen treatment on
consecutive days caused intestinal pathology and death in the CreER
transgenic mice (independent of Dnaic1 status); therefore, in later
studies older animals were studied (z8–12 wk of age), and tamoxifen
was administered every 2 to 3 days. We also observed some ‘‘leakiness’’
of the CreER transgene (i.e., deletion of the targeted allele in the
absence of tamoxifen treatment).
Tracheal Cell Culture
Mouse tracheal epithelial cells were cultured at an air–liquid interface
on 12-mm collagen-coated Millicell-CM culture inserts (0.4 mm pore)
(Millipore Corp., Billerica, MA) essentially as previously described
(24). Ciliary activity was visualized using phase contrast microscopy
and measured using the SAVA program (25) to analyze nine different
low-magnification fields (one central, eight peripheral) from each
insert. For treatment of cultures, tamoxifen was dissolved in ethanol
at 10 mM and diluted in media to a final concentration of 1 mM.
Tamoxifen was added at the time of plating and with each media
change for the first 5 to 6 days of culture. Control cultures were treated
with an equal volume of ethanol.
Generation of a Monoclonal Antibody against Dnaic1
and Western Blotting
Monoclonal antibodies against Dnaic1 were produced by immunization
of mice with the peptide RGTRKRDEDSGTEVGEGTDEC from the
amino terminal of the human DNAI1 protein. All immunization and
screening protocols were performed by the UNC Immunology Core
Facility using standard procedures. For selection of hybridomas, iso-
lated human ciliary axonemes (26) were analyzed by Western blotting.
Additional screenings were performed using a murine Dnaic1-EGFP
fusion protein expressed in 293 cells. For analysis of mouse tracheal
epithelial cells, total cell lysates were prepared in Mammalian Protein
Extraction Reagent (Pierce, Rockford, IL). Ciliary axonemes were
isolated from cultured mouse tracheal epithelial cells as previously
described (26) and prepared in gel-loading buffer. Protein samples
were fractionated on 4 to 12% Bis-Tris gradient gels (Invitrogen,
Carlsbad, CA), transferred to nitrocellulose membranes, and probed
using Amersham ECL Plus reagents (GE Healthcare, Buckinghamshire,
UK), all according to manufacturers instructions.
Quantification of Dnaic1 by PCR
Genomic DNA was isolated from mouse tissues (tail, lung, or trachea)
using the DNeasy Kit according to the manufacturers’ instructions
(Qiagen).
DNA concentrations were determined by spectrophotometry. Real-
time PCR was performed using a Roche Lightcycler 4.0 and the
Lightcycler FastStart DNA Master SYBR green I kit (Roche Applied
Science). Primers specific to exons 17 and 18 were used to analyze the
amount of intact Dnaic1 (see Table E1 in the online supplement). Each
sample was analyzed in duplicate. Relative changes in the level of
intact Dnaic1 (wild-type remaining) were calculated from the efficiency
of the PCR reaction and the cross-point deviation between samples of
Dnaic1flox/flox, Dnaic1wt/flox and their wild-type littermate control ani-
mals and determined by normalization to the reference gene b-ENaC
(Scnn1b) (27).
Measurement of Mucociliary Clearance in the Nasopharynx
To determine the rate of clearance of endogenous mucus from the
upper airways, animals were killed by CO2 asphyxiation, and the lower
jaw was removed. Using a sharp scalpel, an incision was made through
the skin and fascia over the most caudal palatine fold (for an illus-
tration of the relevant mouse anatomy, see Ref. 28). The skin and fascia
were carefully removed from the soft palate by peeling the tissue
caudally using fine forceps. Once the skin and fascia were removed
from the soft palette, the very thin ventral wall of the nasopharyngeal
(NP) meatus was evident, and the beating cilia were clearly seen
clearing debris caudally. The beginning of Video 1 in the online
supplement shows the palatine ridges of the hard palate and upper
molars to the right side, with the exposed NP cavity in the middle of the
field. Water-equilibrated mineral oil was applied to the membrane to
prevent desiccation. Because the cilia are on the opposite side of the
membrane (and the NP cavity is not actually opened), the mineral oil
does not contact the cilia. The entire process can be completed in less
than 5 minutes, and MCC can usually be visualized for up to 30 minutes
after death. For image acquisition, the preparation was placed under
a dissecting scope. A video camera (MTI, Michigan City, IN) was
mounted on the scope and interfaced with a VHS recorder and
monitor. Before MCC was recorded, a slide micrometer was placed
on the stage of the dissecting scope to calibrate distance measurements.
Once the video was recorded, MCC was determined by playing the
video back and determining the time it took particles to traverse
a calibrated distance (corresponding to an in vivo distance of 0.5–1 mm)
on the monitor screen. Usually, 5 to 10 particles were measured, and
the average MCC was calculated as mm/min by an investigator blinded
to the animals’ genotype. For each time point, the rate of MCC is
expressed as a percentage of the control animals studied under the
same conditions at the same time point.
Measurement of Mucociliary Transport in the Trachea
For these studies, we used a modification of previously described
techniques (29, 30). Animals were anesthetized with a mixture of
ketamine/xylazine (90 and 10 mg/kg body weight, respectively), and the
trachea was surgically exposed (not opened). The mouse was then
killed by exsanguination. Using a fine-bore cannula, approximately
500 nl of 0.2% low-melting point agarose containing fluorescent micro-
spheres (1 mm Molecular Probes FluoSpheres, Nile Red; Invitrogen
Corp., Carlsbad, CA) were deposited via the epiglottis in the closed
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trachea near the bifurcation. The mouse was positioned with the head
elevated approximately 108, and the transport of the fluorescent beads
was recorded using a Leica MZ 16FA fluorescent dissecting microscope
and a digital camera. The rate of MCC was determined by measuring
the time required for fluorescent particles to move a measured distance
by an investigator blinded to the animals’ genotype. Usually, 5 to 10
particles were measured for each animal, and the average was taken as
the rate of MCC. For each time point, the rate of MCC is expressed as
a percentage of the control animals studied under the same conditions
at the same time point.
Histology Procedures
After the measurement of MCC by the above methods, the head was
removed, skinned, and fixed in 10% buffered formalin.
After acid decalcification (z 24 h), paraffin sections were prepared
at three different levels of the nasal cavity: one in front of the incisive
papilla, one at the level of the second palatal ridge, and one at the level
of the third molar (z 6, 11, and 28, based on Ref. 31). Sections were
stained with hematoxylin and eosin, alcian blue–periodic acid Schiff (to
visualize mucus accumulation), and alcian yellow–toulidine blue (to
visualize neutrophils and bacteria). For comparisons between groups,
the middle section of each sample was scored from 0 to 4 for the
presence of mucus, neutrophils, and degeneration of the epithelium,
according to the criteria in Figure E1 in the online supplement.
Additional sections were prepared from the mid-brain region and
examined for evidence of hydrocephalus. Typically, a sample of tissue
was taken from the left lung for DNA and RNA analysis, and the four
right lung lobes were fixed by immersion in 4% paraformaldehyde and
stained as described above.
Transmission Electron Microscopy
Tracheal tissue was fixed in fresh 2% paraformaldehyde and 2%
glutaraldehyde with 0.5% tannic acid and processed for transmission
electron microscopy. Images were obtained on a Zeiss 900 TEM at a
magnification of 50,000, and 8 3 10-inch glossy photographs were pre-
pared. Counts of ODAs were obtained from cilia that were in the plane of
focus (with the central pair and radial spokes visible), and one or two cilia
were counted from each image. Image averaging of individual microtu-
bule doublets was performed as previously described (32).
RESULTS
Design of Targeting Construct
To generate a murine model of PCD that closely resembles the
human disease, we targeted the murine homolog of the human
ODA intermediate chain, DNAI1. Mutations in DNAI1 occur
in approximately 10% of patients with PCD, and these patients
exhibit all the features of classic PCD, including otitis media,
chronic rhinosinusitis, bronchiectasis, low levels of nasal nitric
oxide, and situs inversus (19). In addition, all of these patients
demonstrate an almost complete absence of ODAs in respira-
tory cilia examined by electron microscopy. The murine Dnaic1
protein (NP_780347) is 82% identical to the human DNAI1
protein (NP_036276), with a high degree of similarity through-
out the molecule, including several conserved tryptophan-aspar-
tate repeat sequences (WD repeats) that mediate protein–protein
interactions (33). Analysis of Dnaic1 expression by RT-PCR of
various mouse tissues confirmed that murine Dnaic1 is highly
expressed in tissues that contain cilia or flagella (e.g., trachea,
nasal epithelium, and testis) but show little or no expression in
tissues without cilia (e.g., spleen, muscle) (Figure 1). These data
strongly suggested that Dnaic1 was a suitable target for
generating a murine model of PCD. To avoid the high incidence
of neonatal hydrocephalus that occurs in traditional knock-outs
of ciliary genes, we used the Cre-lox system to target the Dnaic1
gene for inducible deletion (23). Many of the mutations that
cause PCD occur in the WD repeat region, including point
mutations that remove a single tryptophan residue at position
568 in one of the WD repeats (19). These WD repeats, which
are conserved in the murine protein, are likely involved in the
assembly of the ODAs (33). Based on sequence analysis and
comparison to the human gene, we have targeted exons 17 and
18 for deletion from the Dnaic1 gene (Figure 2) by inserting
flanking loxP sequences (Dnaic1flox). This in-frame deletion is
predicted to remove 83 amino acids and completely remove one
of the highly conserved WD repeat regions, including the
tryptophan residue corresponding to position 568 in human
DNAI1.
Transgenic animals carrying the correctly targeted Dnaic1
gene were obtained by standard techniques and verified by
sequencing (see MATERIALS AND METHODS). To induce a PCD
phenotype in the respiratory system, it was desirable to induce
the Dnaic1 deletion in essentially all ciliated cells of the upper
and lower airways. To achieve the highest percentage of Cre-
mediated deletion as possible, the Dnaic1flox mice generated
above were crossed with a transgenic line expressing high levels
of a tamoxifen-activated Cre recombinase under control of the
ubiquitous Rosa26 promoter (RosaCreER; Jackson Laboratory).
Effect of Dnaic1 Deletion In Vitro
To determine the effect of the Cre-mediated deletion of Dnaic1
on ciliary activity, tracheal epithelial cells were isolated from
Dnaic1flox/flox mice that were heterozygous for the Rosa/CreER
(Cre1/2) transgene. Control cells were isolated from Dnaic1wt/wt
mice that were also Cre1/2. The cells were plated on collagen
coated inserts in the presence or absence of 1 mM tamoxifen for
the first 6 days of culture. PCR analysis of genomic DNA
Figure 1. Expression of Dnaic1 mRNA in various mouse tissues. RT-PCR
was performed on RNA isolated from the indicated tissues using
primers specific for Dnaic1 mRNA. A strong positive signal was obtained
from tissues with cilia (trachea, nasal) and flagella (testis); other tissues
were negative.
Figure 2. Schematic diagram of the Dnaic1 protein (top) showing the
approximate location of the WD repeats. Diagram of the targeted
genomic region of Dnaic1 (middle) showing the loxP sites flanking
exons 17 and 18. These exons include one of the WD repeat regions.
Activation of CreER with tamoxifen causes the removal of exons 17 and
18 (bottom).
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yielded almost undetectable amounts of intact Dnaic1 in the
tamoxifen-treated Dnaic1flox/flox cultures (Figure 3A). Analysis
of total cellular proteins by Western blotting with a monoclonal
antibody against Dnaic1 (Figure 3B, left panel) demonstrates
the production of the full-length Dnaic1 protein in the Dnaic1wt/wt
cultures (lane 1), whereas only the smaller, deleted Dnaic1
protein is detectable in the Dnaic1flox/flox cultures (lane 3). Both
the full-length and the deleted protein are present in lysates
from heterozygous cultures (lane 2), suggesting that the deleted
protein is stable. As expected, undifferentiated (nonciliated)
cultures do not express detectable Dnaic1 (lane 4). Ciliary
axonemes (Figure 3B, right panel) isolated from Dnaic1wt/wt
and Dnaic1wt/flox cultures show only the full-length Dnaic1 pro-
tein (lanes 1 and 2), and ciliary axonemes from the Dnaic1flox/flox
cultures show no incorporation of the deleted protein (lane 3).
These results clearly show that the full-length Dnaic1 is prefer-
entially incorporated into the cilia of the heterozygote cultures,
whereas the deleted Dnaic1 is incapable of being correctly
assembled into the ODA. After 10 days of culture, the surfaces
of the control cultures were covered with easily visible, actively
beating cilia, whereas only a few actively beating cilia were
observed in the tamoxifen-treated Dnaic1flox/flox cultures. To
determine the percentage of the culture surface covered with
actively beating cilia, video microscopy and computer analysis
were used to determine the area of each field that contained
actively beating cilia. Almost half of the surface of untreated
control (WT) cultures exhibited ciliary activity (46.6%),
whereas untreated cultures from Dnaic1flox/flox mice averaged
38.8% (Figure 3C). Activation of CreER by tamoxifen treat-
ment had a modest effect on ciliary activity in the WT cultures,
reducing the percentage of ciliated surface area to 32.4%. In
contrast, tamoxifen treatment of the Dnaic1flox/flox cultures
resulted in an almost complete inhibition of ciliary activity
(,1.0%). To further confirm that the tamoxifen treatment was
not having a cytotoxic effect or inhibiting ciliated cell differen-
tiation, paraffin sections were prepared and stained with
hematoxylin and eosin at the conclusion of the experiment.
Ciliated cells were clearly visible throughout both cultures
(Figure 3D), and there was no obvious difference between the
control and the tamoxifen-treated culture in the appearance of
the epithelium or the number of ciliated cells.
The above studies demonstrate that the Cre-mediated de-
letion of the targeted exons in Dnaic1 is highly efficient in
culture and results in an almost complete inhibition of ciliary
activity in cultures homozygous for the targeted Dnaic1 allele.
Dnaic1 Deletion Is Efficient In Vivo
To confirm that the tamoxifen treatment chosen (five intraper-
itoneal injections of 75 mg/g; see MATERIALS AND METHODS) was
sufficient to induce the deletion of Dnaic1 in vivo, genomic
DNA was isolated from tail snips of Dnaic1flox/flox Cre1/2
animals before and after treatment with tamoxifen. Comparison
of the genomic DNA samples used for genotyping (before
tamoxifen) with the samples isolated several days after tamox-
ifen treatment by PCR amplification and agarose gel analysis
Figure 3. (A) Genomic DNA
was isolated from untreated
cultures of homozygous loxP/
Dnaic1 (control) or from cul-
tures treated for 6 days with
tamoxifen and amplified with
primers specific to exons 17
and 18. The tamoxifen-treated
cultures demonstrate an al-
most complete absence of
full-length Dnaic1. In the ta-
moxifen-treated culture, the
absence of a specific target
results in the generation of
some nonspecific products.
(B) Western blot analysis of
Dnaic1 expression in mouse
tracheal cells (left panel). Total
cell lysates from differentiated
cultures of wild-type (WT)
(lane 1), Dnaic1flox/Wt (lane 2),
Dnaic1flox/flox (lane 3), and un-
differentiated WT (lane 4)
mouse tracheal epithelial cells
were separated by gel electro-
phoresis and probed with
a monoclonal antibody against
Dnaic1. Cultures from WT
mice express only the full length Dnaic1 protein; cultures of Dnaic1flox/flox cells express only the shorter, deleted protein. Heterozygote cultures
(Dnaic1flox/Wt) express both products; undifferentiated cells express neither. Cilia isolated from cultures of WT (right panel, lane 1) and Dnaic1flox/Wt
(lane 2) cultures show clear incorporation of the full-length protein, whereas cilia isolated from Dnaic1flox/flox cells show no incorporation of the
deleted Dnaic1 protein (lane 3). (C) Ciliary activity in cultures of WT and Dnaic1flox/flox mouse tracheal epithelial cells treated with tamoxifen or
vehicle control. All cultures were positive for the CreER transgene. Cultures were treated for the first 6 days of culture, and ciliary activity was
measured on Day 20. Control cultures averaged greater than 30% ciliated surface area, whereas the PCD cultures averaged less than 1%. Data
shown are from one representative experiment with three cultures in each group and nine measurements per culture (n 5 27 for each condition).
Error bars indicate SEM. (D) Hematoxylin and eosin–stained paraffin section of Dnaic1flox/flox mouse tracheal epithelial cells cultured in the absence
(top) or presence (bottom) of 1 mM tamoxifen. Fully differentiated ciliated cells are abundant in both cultures. Images are representative of two
independent experiments.
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clearly demonstrated Cre-mediated deletion of the loxP tar-
geted Dnaic1 gene (not shown). The level of intact Dnaic1
remaining after tamoxifen treatment (measured by Q-PCR on
tail snips) was almost always less than 15% (average, 10.9 6
1.4%; n 5 23 animals from five experiments). To further
confirm that the deletion was occurring in the primary target
tissue, genomic DNA was also isolated from the trachea or
a portion of the left lung lobe at the conclusion of some studies.
PCR analysis demonstrated the expected pattern of products
from Dnaic1wt/wt, Dnaic1wt/flox, and Dnaic1flox/flox animals (Figure
4A), and Q-PCR using primers specific for the intact Dnaic1
indicated at least 85% deletion in most animals (87.3 6 1.3%;
n 5 15 animals from three experiments; Table E2).
Analysis of RNA isolated from lung tissue of treated animals
also showed the expected distribution of RT-PCR products,
with heterozygous animals expressing both the WT and deleted
alleles and tamoxifen-treated homozygous animals expressing
almost exclusively the deleted allele (Figure 4B).
After treatment with tamoxifen, Dnaic1flox/flox animals
appeared normal and gained weight at the same rate as control
animals. None of the animals displayed physical or behavioral
traits associated with hydrocephalus (e.g., doomed heads, lack
of appetite, ataxia). Examination of histological sections from
the mid-brain region of two groups of animals (n 5 7) at the
conclusion of the experiments (7 and 11 mo after tamoxifen
treatment) showed no indication of enlarged ventricles (not
shown). These data are consistent with the hypothesis that the
development of hydrocephalus due to ciliary dysfunction occurs
during early postnatal brain development (17).
To determine if the deletion of exons 17 and 18 from Dnaic1
would result in ultrastructural defects in the ciliary axoneme,
tracheas were isolated from animals 7 months after tamoxifen
treatment and analyzed by transmission electron microscopy.
Cilia from control mice (Figure 5A) showed the typical 912
pattern of microtubule doublets, with inner and ODAs present
on most cilia. In contrast, cilia from tamoxifen-treated Dnaic1-
flox/flox mice demonstrated an almost complete lack of outer
dynein arms (Figure 5B). The average number of ODAs visible
per cilium in control animals was 8.3 60.3 (n 5 21 cilia from
three animals), whereas cilia from the PCD mice averaged 1.2 6
0.8 ODA per cilium (n 5 14 cilia from two animals). The
absence of ODA in the Dnaic1flox/flox mice can be more clearly
seen in the images obtained by using computer-assisted analysis
to average individual microtubule doublets from several differ-
ent cilia (Figures 5C and 5D) (32).
Dnaic1 Deletion Inhibits Mucociliary Clearance
To generate animals with a PCD phenotype in the absence of
hydrocephalus, animals were not treated with tamoxifen until
the age of 1 to 3 months, which is beyond the critical time pe-
riod for the development of hydrocephalus in other PCD
models (17). However, at the time of tamoxifen treatment, all
animals would already possess a full complement of functional
ciliated cells, and the activation of Cre recombinase was not
expected to immediately result in a PCD phenotype. To de-
termine the time necessary for the deletion of Dnaic1 on the
genomic level to result in a loss of ciliary function, groups of
Dnaic1flox/flox mice that were also Cre1/2 and control animals
were treated with tamoxifen and studied at various times after
treatment. As a measure of mucociliary clearance in the upper
airways, we have developed a technique in which the transport
of endogenous mucus particles in the nasopharynx is quantified.
This method allows visualization and quantification of the rate
of transport of endogenous mucus particles in the closed
nasopharynx, without the addition of exogenous particles or
fluid. In control animals, vigorous MCC can be observed for
periods longer than 10 minutes (Video 1). Six groups of animals
Figure 4. (A) Genomic DNA isolated from lung tissue of tamoxifen
treated mice was amplified by PCR using primers that span the loxP
targeted region of Dnaic1. DNA from WT mice (Dnaci11/1) produced
only the expected 1.4 kb full-length product, DNA from the homozy-
gous loxP/Dnaic1 mouse (Dnaic12/2) produced essentially only the
deleted 564 bp product, and samples from the heterozygous mice
(Dnaic11/2) produced both. (B) RNA isolated from the same tissue as in
A was analyzed by RT-PCR. Note the almost complete absence of intact
Dnaic1 mRNA in the homozygous treated animal (Dnaic12/2).
Figure 5. Transmission electron micrographs of tracheal cilia from (A)
a control mouse (Dnaic1wt/flox) and (B) a mouse with primary ciliary
dyskinesia (PCD) (Dnaic1flox/flox) 7 months after tamoxifen treatment.
Outer dynein arms (ODAs) are clearly visible in cilia from the control
animal but are absent in cilia from the PCD mouse (arrows). Computer-
assisted image averaging of individual outer doublets more clearly
illustrates the presence of the ODA in control axonemes (asterisk in C)
and the absence of ODA in PCD axonemes (asterisk in D). Images
shown are the average of 17 and 27 doublets, respectively.
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were treated with tamoxifen and studied at different times after
treatment ( n 5 52). One month after treatment with tamoxifen,
several of the Dnaic1flox/flox animals displayed substantial rates
of MCC (z20–60% of control), whereas three of seven animals
examined demonstrated no measurable clearance (Figure 6A).
The average rate of MCC in the Dnaic1flox/flox animals was 1.3 6
0.6 mm/min (n 5 7), significantly different from the control
value of 8.9 6 1.7 mm/min (n 5 8; P 5 0.001). Two months after
tamoxifen treatment, three of four animals examined showed no
MCC in the nasopharynx, and the remaining animal exhibited
a drastically reduced rate (1.9 mm/min compared with 10.2 6
1.2 mm/min for control mice; n 5 8). All animals examined at 3
months and eight of nine animals examined at longer time
periods (up to 11 mo) after tamoxifen treatment demonstrated
no MCC in the nasopharynx (Video 2 in the online supplement
and data not shown). These results indicate that 2 to 3 months
after deletion of the Dnaic1 gene, MCC is no longer effective in
the nasopharynx.
In preliminary studies of the trachea, we observed a substantial
amount of ciliary activity in tamoxifen-treated Dnaic1flox/flox
animals up to 3.5 months after treatment, unlike the absence
of MCC in the nasopharynx. To quantify MCC in the lower
airways, we used a modification of several previously described
techniques. Animals were killed, and, after surgically exposing
the trachea, fluorescent microspheres were introduced into the
lower trachea via the epiglottis using a catheter. Transport of
the fluorescent microspheres was then recorded in situ using
a fluorescent dissecting microscope. Three groups of animals
(n 5 28) were treated with tamoxifen, and MCC in the trachea
was measured at various time points. As expected, all control
animals readily transported the particles in a cephalic direction
for several minutes, although clearance in the trachea was not as
robust as observed in the nasopharynx. Three months after
tamoxifen treatment, three of four Dnaic1flox/flox animals clearly
exhibited active MCC in the trachea (Video 3 in the online
supplement illustrates a Dnaic1flox/flox animal with clearance;
Video 4 is from the animal with no clearance), although the rate
of clearance was reduced approximately 50% compared with
control animals (1.1 6 0.5 versus 2.7 6 0.6 mm/min; P 5 0.04;
n 5 4) (Figure 6B). Six months after tamoxifen treatment, three
of four Dnaic1flox/flox mice had no visible MCC, whereas one
animal exhibited a substantially reduced rate of clearance. By
7.5 months, none of the Dnaic1flox/flox animals exhibited
MCC. These results demonstrate that the deletion of exons 17
and 18 of the Dnaic1 gene in adult mice results in a loss of MCC
in both the upper and lower airways but that the loss of MCC in
the nasopharynx occurs more quickly, possibly reflecting a faster
turnover rate of cilia or ciliated cells in the upper airways.
Deletion of Dnaic1 Causes Chronic Rhinosinusitis
We examined the nasal cavity of tamoxifen-treated Dnaic1flox/flox
animals to determine if the deletion of Dnaic1 and the sub-
sequent loss of MCC resulted in pathological changes. All of the
animals that had a complete inhibition of MCC in the naso-
pharynx demonstrated obvious mucus accumulation in the nasal
cavity (Figure 7) regardless of the time at which they were
studied, whereas no mucus was observed in any of the control
animals. Mucus accumulation was clearly present in the nasal
cavity, the maxillary sinuses, or the region of the ethmoturbi-
nates. Most animals had large amounts of mucus in the region of
the ethmoturbinates, although the specific sites of mucus accu-
mulation varied between animals (Figures 7B and 7C) (34).
Some of the mucus-filled areas contained large numbers of in-
filtrating neutrophils (Figures 7B, 7E, and 7G), whereas other
areas contained few or no neutrophils (Figures 7C and 7I).
Routine examination of paraffin sections stained with alcian-
yellow toulidine blue did not reveal the presence of bacterial
colonies. The nasal epithelium was frequently abnormal near
the sites of mucus accumulation, with a loss of normal differ-
entiated epithelial cells and a thinning of the lamina propria
being the most common findings. Evaluation of PCD animals at
different times after treatment revealed no clear trends in the
extent of mucus accumulation, numbers of neutrophils, or tissue
degeneration (Figure E1). However, the amount of epithelial
damage seemed to increase with time after treatment, with
animals examined at early time points (1–3 mo) showing some
areas of normal epithelium in areas of mucus accumulation and
animals examined at later time points (6–11 mo) possessing only
a thin layer of undifferentiated cells over much of the dorsal
meatus and nasal turbinates (Figure 7I). Many of the ethmotur-
binates were severely atrophic, with loss of the surface epithe-
lium, the basal lamina, and the underlying bone (Figure 7I).
In contrast to the nasal cavity, examination of the lungs of
tamoxifen-treated Dnaic1flox/flox animals revealed no mucus
accumulation at any time point (data not shown). In many of
the older animals examined (.6 mo), foci of infiltrating
lymphocytes were observed; however, the size and incidence
of these lesions appeared similar between the Dnaic1flox/flox
animals and the control animals. Therefore, even in mice with
no measurable MCC for approximately 5 months and significant
mucus accumulation in the nasal cavity, the lower airways
showed no evidence of mucus accumulation or infection.
DISCUSSION
Studies of the pathogenesis and treatment of PCD have been
limited, in part due to the small number of patients afflicted
with this disease and in part due to the lack of a suitable animal
Figure 6. Mucociliary clearance (A) in the nasopharynx and (B) in the
trachea of tamoxifen-treated Dnaic1flox/flox mice. Groups of animals
were treated with tamoxifen, and mucociliary clearance (MCC) was
measured at the times indicated and expressed as a percentage of the
rate of MCC in a parallel group of control animals. Complete inhibition
of MCC requires approximately 2 months in the nasopharynx and
approximately 6 months in the trachea after the deletion of Dnaic1.
x axis 5 time after tamoxifen treatment in months. Each symbol
represents a single animal.
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model. Although canids with PCD are occasionally reported in
the literature (35), the time and expense involved has prevented
the development of a canine model. Recent interest in the
expanding roles of cilia in development and disease processes
has led to the development of several mouse lines carrying
deletions of genes involved in ciliary structure and function;
however, if these genes affect motile cilia function in the
ependymal cells, many of the null animals develop hydroceph-
alus during the neonatal period and die (9, 10, 13–17). In
addition, deletion of essential ciliary genes often results in other
developmental abnormalities, including congenital heart defects
(15). Therefore, these models are not well suited for long-term
studies of airway disease caused by PCD or other disorders of
mucociliary clearance. In this work, we have developed and
characterized a genetically modified mouse strain that carries
a conditional loxP targeted deletion in the dynein intermediate
chain gene Dnaic1. Deletion of exons 17 and 18 of the Dnac1
gene by activation of a ubiquitously expressed CreER after the
neonatal period leads to a loss of ODAs, the absence of MCC,
and chronic rhinosinusitis in the absence of hydrocephalus.
These features are consistent with the disease phenotype in
patients with PCD who have mutations in the human homolog
of Dnaic1, demonstrating that our murine model successfully
reproduces key aspects of the human disease in vivo. In vitro,
the deletion of Dnaic1 by tamoxifen treatment of undifferenti-
ated cultures was highly efficient and will provide an essentially
unlimited supply of PCD cells for further studies, including
studies testing the ability of gene therapy vectors to correct the
genetic defect in PCD and restore ciliary activity.
Because the animals in these studies were typically 6 to 10
weeks old at the time of tamoxifen treatment, they already
possessed a full complement of active cilia. Although the
deletion of Dnaic1 at the genomic level occurs relatively
quickly, as evidenced by PCR analysis of genomic tail DNA
several days after treatment, it is not known how long the
already formed cilia and ciliated cells remain functional. Our
data show that MCC is reduced in the nasopharynx 1 month
after the completion of tamoxifen treatment and is completely
eliminated by 3 months. The one animal examined at 2 months
that maintained approximately 20% of the normal rate of MCC
had no evidence of mucus accumulation in the nasal cavity.
Quantitative PCR demonstrated that this animal had approxi-
mately 20% intact Dnaic1 remaining after tamoxifen treatment
(animal #494; Table E2), suggesting that even a low level of
MCC is sufficient to prevent the chronic rhinosinusitis observed
in animals with no MCC. In the trachea, MCC was still apparent
at 3 months, with one animal maintaining some clearance at
6 months. These data suggest that the turnover rate of ciliary
proteins or ciliated cells is faster in the upper airways of mice,
possibly due to the greater exposure of these cells to environ-
mental insults. This is consistent with a previous study that
demonstrated ciliated cells in the lower airways had a half-life
that was significantly longer than those in the trachea (36),
although this study did not investigate the turnover of ciliated
cells of the upper airways. Our model will allow detailed study
of the turnover of ciliary proteins, which may have important
implications for therapy. For example, many of the mutations in
patients with PCD result in premature termination of transla-
tion, and recently drugs have been introduced that promote
read-through of these mutations and allow the production of
some full-length protein (37, 38). It is not known if these agents
can restore ciliary activity to already assembled axonemes.
To avoid the 3 to 6 months required for ciliary turnover and
to develop PCD animals more quickly, it may be possible to use
an alternative CreER to target specific tissues and avoid
expression in the brain. However, our initial goal was to induce
the deletion in all tissues to more closely replicate the human
disease. We also wanted to test the hypothesis that deletion
of Dnaic1 after the neonatal period would not cause hydro-
cephalus. In these studies, we observed no evidence of hydro-
cephalus in animals that were studied up to 11 months after
tamoxifen treatment. This result strengthens the hypothesis that
the activity of ependymal cilia is important to maintain patency
of the aqueduct during early postnatal brain development but
may not be essential in the adult animal (17). Similarly, we did
not observe histologic evidence of otitis media in Dnaic1flox/flox
animals treated with tamoxifen (n 5 7), perhaps because the
deletion of Dnaic1 in our model occurred in older animals.
Although otitis media is a common feature of human PCD, it has
not been consistently reported to occur in mouse models of PCD.
Figure 7. Rhinosinusitis in PCD mice. (A)
Paraffin section of a control mouse (11
mo) showing the nasal septum (1), the
ethmoturbinates (2), and the maxillary
sinus (3). Nasal cavity of representative
PCD mice 2 (B) and 11 (C) months after
Dnaic1 deletion. Higher magnification
images of ciliated epithelium from the
maxillary sinus (D, E) and olfactory epi-
thelium (F, G) of a control (D, F) and of
the PCD mouse (E, G) shown in B. Note
the accumulation of mucus and inflam-
matory neutrophils and the degeneration
of the epithelium in the PCD animal. (H
and I) Low-magnification images of the
ethmoturbinates from the animals shown
in A and C, showing the attenuation of
epithelium and the underlying bone
structure in the PCD mouse. A, B, and C
were stained with alcian blue–periodic
acid Schiff; D, E, H, and I were stained
with hematoxylin and eosin; F and G were
stained with alcian blue–toluidine yellow.
Scale bars for D, E, F, and G 5 10 mm;
scale bars for H and I 5 40 mm.
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In addition to the time required for ciliary turnover, the use
of an alternative Cre line would be preferable for other reasons.
In our initial studies, we observed toxic effects of the Cre
transgene when animals were treated with tamoxifen at younger
ages or received more frequent treatment. These animals
developed intestinal lesions, and some died, possibly due to
nonspecific, Cre-mediated DNA damage in the rapidly pro-
liferating intestinal epithelium. In addition, the Rosa/CreER
displayed some activity in the absence of tamoxifen treatment,
so that in some litters we observed animals with ‘‘spontaneous’’
deletion of the targeted alleles. This occasionally resulted in the
birth of homozygous Dnaic1 null animals; these animals were
invariably runted, showed evidence of hydrocephalus, and
several displayed situs inversus at necropsy. The use of the
more tightly regulated CreERT2 or a tissue-specific promoter
may alleviate these problems.
Chronic rhinosinusitis is one of the most common symptoms
of PCD and is the cause of significant morbidity in the general
population. In our studies, 100% of the mice with no MCC
in the nasopharynx developed rhinosinusitis, with mucus accu-
mulation, infiltrating neutrophils, and epithelial degeneration.
Mucus accumulation was observed predominantly in the dorsal
meatus and the adjacent ethmoturbinates, but mucus was also
observed adjacent to the nasal septum and in the maxillary
sinuses. Other investigators have reported similar findings in
other mouse lines with deletions of ciliary genes (12–14, 39);
together, these studies demonstrate the importance of normal
ciliary activity to the upper (nasal) airways of the mouse. Re-
cent studies have also demonstrated impaired ciliary activity in
studies of humans with chronic rhinosinusitis (40, 41).
In contrast, animals with no measurable MCC in their lower
airways (trachea) showed no evidence of pulmonary disease for
periods up to 11 months after tamoxifen treatment. This is also
consistent with the lack of a reported lower airway phenotype in
other mouse models with dysfunctional cilia (e.g., Refs. 11–13),
although because the Dnaic1flox/flox mice did not develop hy-
drocephalus, our studies were of a significantly longer duration.
The lack of a disease phenotype in the lower airways suggests
that mice are able to clear secreted mucus and inhaled
pathogens sufficiently by means other than MCC to prevent
accumulation and subsequent disease. One alternative mecha-
nism that has been proposed to aid in airway clearance is gas–
liquid pumping (42, 43), and our mouse model should provide
an ideal system for determining the importance of this mech-
anism. Because of the complex architecture of the nasal
turbinates and the limited airflow through the sinuses, gas–
liquid pumping may be insufficient to clear mucus from these
regions. Another reason that animals with no MCC did not
develop significant pulmonary disease in this study may be
because laboratory animals are housed in facilities that mini-
mize spontaneous exposure to pathogens. Under conditions of
limited exposure to bacterial pathogens, it is likely that the
mouse immune system is more than sufficient to prevent lung
infection. We observed no evidence of bacterial infection in
these studies, even in mice with severe mucus accumulation in
the nasal cavity. Controlled challenges with increasing doses of
bacteria delivered directly to the lower airways of tamoxifen-
treated Dnaic1flox/flox animals would be expected to result in
more severe or prolonged disease than in control animals, and
future studies will test this hypothesis.
In summary, we have developed and characterized a mouse
model for PCD that avoids the development of hydrocephalus
that frequently occurs when ciliary genes are disrupted. We
have also developed methods for quantitatively measuring
MCC in vivo in the upper and lower airways under conditions
in which the airway being studied remains intact and little or no
exogenous fluid is added. These studies have demonstrated that
the loss of MCC and the apparent turnover of ciliated cells
occur more slowly in the lower airways than in the nasopharynx.
Tamoxifen-treated Dnaic1flox/flox animals reproduce several
features of human PCD, including an absence of ODAs in
airway cilia examined by electron microscopy, an absence of
MCC in the nasopharynx and trachea, and the development of
severe rhinosinusitis. This model will be useful for studies of the
pathogenesis and treatment of PCD and chronic rhinosinusitis
and for studies of airway clearance and respiratory cilia. The
inducible inactivation of Dnaic1 may provide a tool for in-
vestigations into other cilia related disorders, including hydro-
cephalus, congenital heart defects, and infertility.
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